Theralink Technologies

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel cancer immunotherapy products using patented vaccine technology, designed to stimulate the immune system to selectively attack cancer cells without harming the patient. The vaccine technology has been proven safe in over 300 patients, with no single serious adverse event reported. OncBioMune Pharmaceuticals' prostate cancer product, ProscaVax™, is nearing completion of its Phase I trial funded by the Department of Defense Navy Cancer Vaccine Program.On September 24, 2020, OncBioMune Pharmaceuticals, Inc. announced the completion of a corporate name change, with the new name being Theralink Technologies, Inc.